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Abstract
Background: To develop antibacterial agents having novel modes of action against bacterial cell
wall biosynthesis, we targeted the essential MurF enzyme of the antibiotic resistant pathogen
Pseudomonas aeruginosa. MurF catalyzes the formation of a peptide bond between D-Alanyl-D-
Alanine (D-Ala-D-Ala) and the cell wall precursor uridine 5'-diphosphoryl N-acetylmuramoyl-L-
alanyl-D-glutamyl-meso-diaminopimelic acid (UDP-MurNAc-Ala-Glu-meso-A2pm) with the
concomitant hydrolysis of ATP to ADP and inorganic phosphate, yielding UDP-N-acetylmuramyl-
pentapeptide. As MurF acts on a dipeptide, we exploited a phage display approach to identify
peptide ligands having high binding affinities for the enzyme.
Results: Screening of a phage display 12-mer library using purified P. aeruginosa MurF yielded to
the identification of the MurFp1 peptide. The MurF substrate UDP-MurNAc-Ala-Glumeso-A2pm
was synthesized and used to develop a sensitive spectrophotometric assay to quantify MurF kinetics
and inhibition. MurFp1 acted as a weak, time-dependent inhibitor of MurF activity but was a potent
inhibitor when MurF was pre-incubated with UDP-MurNAc-Ala-Glu-meso-A2pm or ATP. In
contrast, adding the substrate D-Ala-D-Ala during the pre-incubation nullified the inhibition. The
IC50 value of MurFp1 was evaluated at 250 μM, and the Ki was established at 420 μM with respect
to the mixed type of inhibition against D-Ala-D-Ala.
Conclusion: MurFp1 exerts its inhibitory action by interfering with the utilization of D-Ala-D-Ala
by the MurF amide ligase enzyme. We propose that MurFp1 exploits UDP-MurNAc-Ala-Glu-meso-
A2pm-induced structural changes for better interaction with the enzyme. We present the first
peptide inhibitor of MurF, an enzyme that should be exploited as a target for antimicrobial drug
development.
Background
The bacterial cell wall biosynthesis pathway represents the
most validated source of antibacterial targets. The path-
way encodes essential and highly conserved enzymes with
no eukaryotic counterparts, the inhibition of which lead-
ing to bacterial cell death [1]. The first step of the pathway
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is catalyzed by the cytoplasmic enzymes MurA through
MurF, which synthesize UDP-N-acetylmuramyl-pen-
tapeptide (Figure 1). Membrane translocases MraY and
MurG then add the undecaprenyl-phosphate lipid carrier
and N-acetylglucosamine to form lipid II. This precursor
is translocated to the periplasm and linked to the growing
cell wall polymer by the transglycosylation and
transpeptidation actions of penicillin-binding proteins
(PBPs). The cell wall layer, composed of alternating units
of UDP-N-acetylglucosamine and UDP-N-acetylmuramic
acid cross-linked via short peptide chains (Figure 1),
maintains cell shape and integrity [2].
While several clinically useful antibiotics interfere with
this pathway [3,4], no antibacterial agents target the ATP-
dependent Mur ligase enzymes (MurC, MurD, MurE and
MurF) that perform the non-ribosomal stepwise addition
of the five amino acids forming the cell wall peptide moi-
ety (Figure 1). This under-exploitation may be partially
explained by the lack of commercially available nucle-
otide substrates for studying these enzymes [3,5].
We selected MurF as a specific target. MurF catalyzes the
formation of a peptide bond between D-Ala-D-Ala and
the nucleotide precursor UDP-N-acetylmuramoyl-L-ala-
nyl-D-glutamyl-meso-diaminopimelic acid (UDP-Mur-
NAc-Ala-Glu-meso-A2pm) with the concomitant
hydrolysis of ATP to ADP and inorganic phosphate, yield-
ing UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-meso-
diaminopimelyl-D-alanyl-Dalanine [6]. While the roles of
MurC, MurD and MurE may be substituted in a single step
by the muropeptide ligase Mpl involved in cell wall recy-
cling [7], MurF remains the sole D-Ala-D-Ala adding
enzyme [8,9]. The MurF active site is highly conserved
among all medically relevant bacteria [10]. Strict limita-
tion to D-amino acid substrates [5] also makes MurF an
especially attractive target for the development of antibac-
terial agents. These amino acids are metabolized only in
prokaryotes [11], and D-Ala-D-Ala plays a critical role in
cell wall cross-linking [12]. Furthermore, normally func-
tioning MurF is essential for proper cell division, optimal
expression of methicillin resistance in Staphylococcus
aureus  [9,13] and glycopeptide resistance mechanism
[14,15].
Since MurF acts on a dipeptide to form bonds of a highly
distinctive type, we investigated the possibility of inhibit-
ing this enzyme with peptide ligands from a phage display
library. Phage display screening allows the selection of
peptides having specific binding affinities for a targeted
protein and has proven useful for identification of various
enzyme inhibitors including MurC and MurD [16-18].
The results we present herein constitute the first report of
a peptide inhibitor of MurF. We focused this effort on the
Gram-negative bacterium Pseudomonas aeruginosa, an
ubiquitous opportunistic pathogen responsible for a vari-
ety of chronic nosocomial infections such as lung infec-
tion in cystic fibrosis patients [19]. P. aeruginosa is one of
the most difficult microorganisms to combat due to high
level of resistance to most antibiotics [20].
Results
Purification of biologically active MurF enzyme
The purified MurF protein was visualized as a single 52
kDa band on SDS-PAGE (data not shown). N-terminal
sequencing of the first 15 amino acid residues confirmed
its identity as P. aeruginosa MurF ligase [Swiss-Prot:
Q9EY48, PIR: SF001562] (100% identical to the pub-
lished sequence, including the initial Met). MurF biologi-
cal activity was confirmed by mass spectrometric
identification of the cytoplasmic cell wall precursor UDP-
N-acetylmuramyl pentapeptide synthesized in vitro in the
presence of the purified enzymes MurA, MurB, MurC,
MurD and MurE [21].
Affinity selection of MurF binding peptides
As shown in Table 1, each of the three rounds of bio-pan-
ning selected only a fraction of the phage input, which
decreased from approximately 1011 down to 107 plaque
forming units (PFUs). The third round gave a lower phage
recovery compared to the two previous rounds, indicating
a strong selection of specific MurF-interacting peptide
sequences at this step. Each elution strategy employed at
the end of the third round gave similar phage recovery
yields. Indeed, the competitive elution conditions using
specific MurF substrates were as effective as the well-
known glycine-HCl elution strategy.
The different elution conditions allowed the selection of
different peptide sequences with specific motifs (Figure
2). Analysis of the frequency of peptide sequence recovery
and conserved motifs identified the consensus sequence
TMGFTAPRFPHY, called MurFp1. This peptide sequence
was principally selected by the glycine-HCl elution strat-
egy and was also recovered by competitive elutions (Fig-
ure 2). MurFp1 was rich in hydrophobic aromatic
residues, P residues and basic residues but contained no
acidic or polar residues. The N-terminal T residue and the
basic R residue of MurFp1 were particularly conserved,
especially in the ATP and D-Ala-D-Ala elution groups.
Two hydrophobic aromatic residues or two P residues
often occurred close to each other in the selected peptide
sequences as they do in the consensus sequence. P resi-
dues occurred mostly near a hydrophobic aromatic resi-
due or a basic residue, as in MurFp1 sequence (Figure 2).
Apart for MurFp1 found in more than one elution group,
the sequence VSANRHLGGNLP indicated by a star in Fig-
ure 2 was recovered once by both the ATP and D-Ala-D-
Ala elutions. Elution with glycine-HCl gave two sequences
with a "SRL" motif, which was absent in the other elutionBMC Biochemistry 2008, 9:33 http://www.biomedcentral.com/1471-2091/9/33
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Schematic representation of the bacterial cell wall biosynthesis pathway Figure 1
Schematic representation of the bacterial cell wall biosynthesis pathway. The cytoplasmic, membrane and periplas-
mic steps of the pathway are shown, along with the structure of the cell wall layer product, composed of alternating units of 
UDP-N-acetylglucosamine and UDP-N-acetylmuramic acid cross-linked via short peptide chains.
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groups. Among the ATP elution group, two sequences pre-
sented a "YST" motif also absent in the other elution
groups. The vast majority of the sequences eluted with D-
Ala-D-Ala presented hydrophobic residues near small res-
idues. The D-Ala-D-Ala elution group recovered more
small amino acids than the other groups. Overall, the
competitive elutions yielded to more sequence diversity
than the glycine-HCl elution.
Bioinformatic analysis
The theoretical pI of MurFp1 was 8.44, indicating that the
peptide would be positively charged at physiological pH.
MurFp1 contains a single amino acid (R) that would bear
this positive charge and no amino acid bearing a counter-
balancing negative charge. The ProtParam tool estimated
the half-life of MurFp1 at more than 10 hours in
Escherichia coli in vivo and at 7.2 hours in mammalian
reticulocytes in vitro. The secondary structure prediction
tools indicated with relative certainty a random coil struc-
ture. The fasts34 program did not identify any relevant
protein in the UniProt database having similarities to
MurFp1.
Synthesis and purification of UDP-MurNAc-Ala-Glu-meso-
A2pm
Analysis of UDP-MurNAc-Ala-Glu-meso-A2pm synthe-
sized by the P. aeruginosa enzymes MurA, MurB, MurC,
Table 1: Phage titers obtained after each round of bio-panning 
using MurF and the 12-mer library
Phage input Eluted phages Elution (%)
Round 1
Gly-HCl 4 × 1010 8.2 × 106 2 × 10-2
Round 2
Gly-HCl 1.5 × 1011 4.1 × 107 2.7 × 10-2
Round 3
Gly-HCl 2 × 1013 1.1 × 107 5.5 × 10-5
ATP 1.3 × 107 6.5 × 10-5
D-Ala-D-Ala 5.6 × 106 2.8 × 10-5
Peptide sequences selected after the third round of bio-panning against MurF Figure 2
Peptide sequences selected after the third round of bio-panning against MurF. Acidic amino acids (D, E) are in tur-
quoise blue, polar amino acids (Q, N) are in light green, basic amino acids (K, R, H) are in blue, hydrophobic amino acids (I, L, 
M, V) are in pink, hydrophobic aromatic amino acids (F, Y, W) are in red, small amino acids (A, S, C, T) are in magenta, G is in 
orange, and P is in black (classified according to the Venn diagram for defining the relationships between amino acids). The 
MurFp1 consensus sequence and related conserved motifs are boxed in black, and the star indicates the other peptide 
sequence recovered more than once.
TMGFTAPRFPHY
TMGFTAPRFPHY
TMGFTAPRFPHY
TMGFTAPRFPHY
TPEPLKPSRLYQ
THYVKPTLMSIQ
KPYNLYSGANQP
FPISRLTALVPP
IDRTPTNFHTQR
QHTHSKYLPRVL
TMGFTAPRFPHY
TLPAFGPRAHVL
YFPGPDARMALL
NLLTSNSHWPPR
NSLTDPLHVYST
HFPSAHPTYSTN
VSANRHLGGNLP*
SVSVGMKPSRRP
TMGFTAPRFPHY
THPWSLKTTSFS 
TPLKSHSVARNS
LPYTATLSLSIK
VHRDLSGRFDPG
SSYAQFARLPVP
ISTSNPRHHSTA
VSANRHLGGNLP*
ANLSMFATRLIT
HWSSGQALLSLR
Gly ATP D-Ala-D-Ala
Consensus: TMGFTAPRFPHYBMC Biochemistry 2008, 9:33 http://www.biomedcentral.com/1471-2091/9/33
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MurD and MurE by FPLC anionic exchange indicated a
purity of 95%. The structure of the purified UDP-MurNAc-
Ala-Glu-meso-A2pm product was confirmed by mass
spectrometry (data not shown).
Characterization of MurF activity
The controls performed without MurF or without any one
of the substrates did not yield any phosphate from ATP
(data not shown), indicating that the reaction mixture was
devoid of contaminating ATPase activities that might
interfere with the assay. The optimal ATP concentration
was 1 mM and MurF reached noticeable activity with 100
μM of UDP-MurNAc-Ala-Glu-meso-A2pm (data not
shown). Steady state kinetic analysis indicated that MurF
obeyed Michaelis-Menten kinetics, reaching a maximal
specific activity of 4.4 ± 0.4 μmole/min/mg at 5 mM D-
Ala-D-Ala with a Km of 115 ± 10 μM (Table 2). Addition
of NaCl to the reaction buffer improved MurF activity by
a factor of 1.75 (data not shown). The enzyme was very
sensitive to the buffer pH, with maximal activity at pH 8.6.
The kcat value indicated that each MurF active site per-
formed about 100 ligations of D-Ala-D-Ala to UDP-Mur-
NAc-Ala-Glu-meso-A2pm and hydrolyzed about 100 ATP
molecules per min, releasing the same amount of ADP
and inorganic phosphate in accordance with the known
stoichiometric relationship (Table 2) [22].
Inhibitory kinetics of MurFp1
MurFp1 was first shown to be a weak time-dependent
inhibitor of MurF. The inhibition increased as a function
of pre-incubation time, following an overall linear rela-
tionship. At a concentration of 2 mM, MurFp1 inhibited
50% of MurF activity subsequent to a 30-minute pre-incu-
bation time (Figure 3).
Adding UDP-MurNAc-Ala-Glu-meso-A2pm or ATP dur-
ing the pre-incubation step unexpectedly increased the
inhibitory action of MurFp1, an effect less pronounced for
ATP (data not shown). MurF reaction velocity in the
absence of inhibitor was similar with or without UDP-
MurNAc-Ala-Glu-meso-A2pm or ATP in the pre-incuba-
tion step. MurFp1 inhibited MurF eight times more effi-
ciently when UDP-MurNAc-Ala-Glu-A2pm was added to
the 30-minute pre-incubation step, giving an IC50 value of
250 ± 10 μM. The inhibition curve displayed a linear dose-
response trend having variable slopes as shown in Figure
4.
The presence of D-Ala-D-Ala during the pre-incubation
step nullified the inhibition of MurF by MurFp1 (data not
shown). MurF reaction velocity in the absence of inhibitor
was nearly identical with or without D-Ala-D-Ala in the
pre-incubation step. The Ki of MurFp1 was determined
with respect to the D-Ala-D-Ala substrate, with a 30 min
pre-incubation of MurF with UDP-MurNAc-Ala-Glu-
Table 2: Kinetic characterization of the MurF enzyme velocities 
in respect to the D-Ala-D-Ala substrate
Kinetic parameters MurF
Specific activity (μmol/min/mg) 4.4 ± 0.1
kcat (min-1) 100 ± 15
Km (μM) 115 ± 10
kcat/Km (min-1 μM-1) 0.85 ± 0.15
Inhibition of MurF activity by MurFp1 as a function of pre- incubation time Figure 3
Inhibition of MurF activity by MurFp1 as a function of 
pre-incubation time. Experiments were done following 
different pre-incubation times of MurF with 2 mM of MurFp1.
IC50 determination for the inhibition of MurF activity by  MurFp1 Figure 4
IC50 determination for the inhibition of MurF activity 
by MurFp1. Experiments were done following a 30 min of 
pre-incubation step with MurF, MurFp1 and UDP-MurNAc-
Ala-Glu-A2pm.BMC Biochemistry 2008, 9:33 http://www.biomedcentral.com/1471-2091/9/33
Page 6 of 11
(page number not for citation purposes)
A2pm and MurFp1. The Km values of MurF for D-Ala-D-
Ala remained almost the same for each MurFp1 concen-
tration used to determine the Ki while the Vmax of MurF
decreased significantly as a function of MurFp1 concentra-
tion (Figure 5A and Table 3). At 600 μM MurFp1, the Vmax
of MurF was three times lower than for the uninhibited
reaction (Table 3). The slopes and the y-intercept of the
fitted lines of the Lineweaver-Burk plot varied with
MurFp1 concentration (Figure 5B), indicating a catalytic
and specific component in the inhibition. The common
intersection point of the fitted lines of the Lineweaver-
Burk plot was positioned at the left of the ordinate and
below the abscissa (Figure 5B), indicating a reversible
mixed type of inhibition against D-Ala-D-Ala. This inhibi-
tion type was further identified as the most suitable model
of inhibition, based on statistical convergence to the
experimental data according to the Runs Test, giving the
highest R2 value (0.97), the lowest Akaike value (-275)
and the lowest standard deviation of the residuals (0.15).
The non-competitive type of inhibition was the second
best model, giving statistical values close to the mixed
model of inhibition (data not shown). The Ki value of
MurFp1 was 420 ± 100 μM for the mixed type of inhibi-
tion against D-Ala-D-Ala, and 370 ± 55 μM for the non-
competitive model. The a parameter indicated that
MurFp1 binding to the MurF-D-Ala-D-Ala complex (ES)
did not significantly change MurF affinity for D-Ala-D-
Ala. The β parameter indicated that the rate constant of ES
breaking down to enzyme and product dropped when
MurFp1 was bound to ES (Table 3).
A non-specific 12-mer peptide pre-incubated for 30 min
with MurF with or without UDP-MurNAc-Ala-Glu-A2pm
did not inhibit MurF activity (data not shown). The reac-
tions were performed in the presence of excess bovine
serum albumin, suggesting that MurFp1 did not interact
non-specifically with proteins.
Discussion
Phage display screening of MurF yielded to the identifica-
tion of the peptide inhibitor MurFp1. The reduction of the
contact time between the phages and MurF during the
third round of bio-panning allowed the selection of spe-
cific MurF-interacting peptides. This selection pattern was
also observed for phage display screening of the amide
ligase MurD [18]. In contrast, selection of specific MurC-
interacting peptides occurred earlier in the phage display
screening [17]. Phage display screenings of P. aeruginosa
proteins FtsA, FtsZ, MurC, MurD and MurF done under
similar conditions did not identify any redundant
sequences [17,18,23,24].
The ATPase activity of MurF has been shown to depend on
the presence of both D-Ala-D-Ala and UDP-MurNAc-Ala-
Glu-A2pm [22]. We developed a simple, rapid, sensitive,
reliable and inexpensive assay to quantify MurF ATPase
activity using the Lanzetta reagent. In opposite to other
methods used to measure MurF enzymatic activity
[6,8,14,22,25-36], our assay does not involve any radioac-
tive isotope or additional enzyme, making high-through-
put screening for MurF inhibitors more suitable. The
maximal specific activity measured with this assay (4.4
μmole/min/mg) is comparable to the published value for
the  P. aeruginosa MurF enzyme (3.41 μmole/min/mg)
[34]. The Km value determined for D-Ala-D-Ala with P.
aeruginosa MurF (115 μM) is in the same range as values
published previously for this enzyme and for its E. coli,
Bacillus  and  Streptococcus faecalis equivalents [6,14,25-
27,32,37]. This Km value is roughly equal to the concentra-
tion of the D-Ala-D-Ala intracellular pool in E. coli, estab-
lished at 200 μM [6,29].
It has been shown that the binding order for substrates to
Mur ligases begins with ATP, followed by the nucleotide
substrate and ending with the amino acid [6,38]. It has
been further demonstrated that the nucleotide substrate
binds efficiently to MurD without ATP, inducing confor-
mational changes in the C-terminal and N-terminal
domains of the protein [39]. To explain how MurFp1
could be a stronger inhibitor following pre-incubation
with UDP-MurNAc-Ala-Glu-meso-A2pm, we hypothesize
that binding of the nucleotide substrate to MurF induces
a structural change that optimizes binding and/or activity
of MurFp1. E. coli MurF crystal structure indicates that
UDP-MurNAc-Ala-Glu-meso-A2pm interacts mainly with
the N-terminal domain, ATP binds principally to the cen-
Table 3: Kinetic characterization of MurF inhibition by MurFp1 
with respect to D-Ala-D-Ala.
Kinetic parameters [MurFp1] (μM) Value
IC50 (μM) 250 ± 10
Vmax (nmol/min) 0 0.61 ± 0.01
75 0.49 ± 0.01
150 0.4 ± 0.01
300 0.36 ± 0.02
600 0.22 ± 0.01
Km (μM) 0 115 ± 10
75 100 ± 10
150 85 ± 5
300 140 ± 30
600 115 ± 25
Mixed α 0.85 ± 0.25
Mixed β 8.5 × 10-10 ± 0.6 × 10-10
Mixed Ki (μM) 420 ± 100
Non-competitive β 8 × 10-10 ± 0.7 × 10-10
Non-competitive Ki (μM) 370 ± 55
Kinetic parameters were monitored with a pre-incubation of 30 min 
with MurF, MurFp1 and UDP-MurNac-Ala-Glu-meso-A2pm.BMC Biochemistry 2008, 9:33 http://www.biomedcentral.com/1471-2091/9/33
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tral domain and D-Ala-D-Ala interacts at the C-terminus
[40]. The N-terminal domain of MurF binds the uracyl
ring of UDP but does not present the typical nucleotide-
binding fold. Indeed, part of the central domain of MurF
extends out towards the N-terminal domain to bind the
pyrophosphate portion of the nucleotide substrate [40].
This suggests a conformational change upon UDP-Mur-
NAc-Ala-Glu-meso-A2pm binding and could explain why
ATP binding to the central domain also increased inhibi-
tion by MurFp1. To our knowledge, we have presented the
first compound having Mur ligase inhibitory action that is
enhanced by pre-incubation with the nucleotide sub-
strate. However, appropriately substituted phosphinate
inhibitors of ATP-dependent amide-forming enzymes
depend on their phosphorylation via the ATP substrate.
These ATP-dependent phosphinate analogues exhibit a
transition-state time-dependent inhibition closely mim-
icking the tetrahedral intermediate involved in Mur ligase
reactions [3].
Based on classical interpretation of our kinetic and statis-
tical data, MurFp1 is a reversible mixed inhibitor. MurFp1
acted as a competitive inhibitor since the inhibition was
reversed by addition of D-Ala-D-Ala during pre-incuba-
tion, and the slopes of fitted lines from Lineweaver-Burk
plot increased as a function of MurFp1 concentration,
revealing an increase in inhibitor binding strength
[41,42]. Like a non-competitive inhibitor that interferes
with substrate utilization without directly competing for
the substrate binding site, MurFp1 inhibits MurF at high
or low substrate concentrations, the Vmax of MurF decreas-
ing as a function of MurFp1 concentration and the y-inter-
cept of Lineweaver-Burk plot varying as a function of
MurFp1. MurFp1 appears not to alter MurF affinity for D-
Ala-D-Ala but rather inhibit breakdown of the enzyme-
substrate complex to enzyme and product. Indeed,
MurFp1 acted more like a non-competitive inhibitor than
a competitive inhibitor. MurFp1 must bind elsewhere
than at the D-Ala-D-Ala binding site. However, phage dis-
play and kinetic data indicated that D-Ala-D-Ala released
MurFp1 from the MurF surface. We speculate that D-Ala-
D-Ala interaction with MurF can enhance conformational
changes that displace MurFp1. It should be noted that the
glycine elution yielded to a better selection of MurFp1
than the D-Ala-D-Ala competitive elution. Furthermore,
reversion of the inhibition is only noticeable when D-Ala-
D-Ala is added to the pre-incubation step without the two
remaining substrates. In a physiologic environment, such
nullification of the inhibition would not be expected as
MurFp1 inhibits MurF at high D-Ala-D-Ala concentra-
tions. Since D-Ala:D-Ala ligases (DDl, see Figure 1) are
highly sensitive to feed-back inhibition by their D-Ala-D-
Ala product [37], the inhibitory potential of MurFp1 may
be amplified in physiologic conditions.
MurFp1 could exert inhibition by sequestering D-Ala-D-
Ala or interfering with MurF structural changes necessary
for substrate proximity and amide bond formation [40]. It
will be of primary interest to investigate the exact binding
site of MurFp1 and whether it affects MurF conformation
by co-crystallization of the MurF-MurFp1 complex with
each individual substrate. This will yield valuable infor-
Kinetics of MurF inhibition by MurFp1 with respect to D-Ala-D-Ala Figure 5
Kinetics of MurF inhibition by MurFp1 with respect to D-Ala-D-Ala. A) Michaelis-Menten and B) Lineweaver-Burk 
plots for MurF activity with respect to the D-Ala-D-Ala substrate showing inhibition by MurFp1 at 0 μM (●), 75 μM (■), 150 
μM (▲), 300 μM (▼) and 600 μM ().BMC Biochemistry 2008, 9:33 http://www.biomedcentral.com/1471-2091/9/33
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mation for further directed optimization of the inhibitor
by medicinal chemistry and peptidomimetism [43].
Conclusion
As a first step into the development of novel inhibitors tar-
geting unexploited bacterial targets, we have identified the
first peptide inhibitor of the essential MurF amide ligase
enzyme using a phage display approach. The nucleotide
substrate UDP-MurNAc-Ala-Glu-meso-A2pm was synthe-
sized and used to develop a sensitive MurF enzymatic
assay. The 12-mer peptide MurFp1 acted as a time-
dependent inhibitor of MurF activity and its inhibitory
potential increased significantly when MurF was pre-incu-
bated with UDP-MurNAc-Ala-Glu-meso-A2pm. MurFp1
presumably exploits UDP-MurNAc-Ala-Glu-meso-A2pm-
induced structural changes for better interaction with the
enzyme. The peptide inhibits the utilization of D-Ala-D-
Ala by MurF, preventing the breakdown of the enzyme-
substrate complex to enzyme and product with an IC50
value of 250 μM and a Ki value of 420 μM. The discovery
of this unique inhibitor opens the path to the rational
design of a new generation of antibacterial agents inhibit-
ing the bacterial cell wall biosynthesis.
Methods
MurF enzyme preparation
The MurF protein was over-expressed, purified and
sequenced as previously described [21]. All reagents were
from Sigma Aldrich (Oakville, Ontario, Canada) unless
otherwise indicated. Phosphate in the MurF preservation
buffer was removed by dialyzing 5 ml against 3 L of buffer
A (25 mM Bis-Tris Propane pH 8.0, 1 mM β-mercaptoeth-
anol, 2.5 mM MgCl2) three times at 4°C. Purified MurF
was visualized on SDS-PAGE using a SYPRO ® Orange
staining (Bio-Rad Inc., Mississauga, Ontario, Canada) and
the protein concentration was determined by the Bradford
method (BioRad Inc., Mississauga, Ontario, Canada)
using bovine serum albumin as standard. The phosphate-
free MurF protein was aliquoted and preserved at -20°C
with glycerol a final concentration of 10%.
Affinity selection of phage displayed peptides against 
MurF
Phage display screening was performed with the PH.D.-12
phage library (New England Biolabs, Mississauga,
Ontario, Canada). Peptide permutations are fused to the
minor coat protein pIII of phage M13 via the flexible
linker Gly-Gly-Gly-Ser. Three rounds of bio-panning were
performed with increasing specificity obtained by increas-
ing the Tween concentration during washes and decreas-
ing the time of contact between the phages and the
targeted protein as previously described [17,23]. Phages
encoding selected peptides were eluted at the end of the
third round using 100 μl of 0.2 M glycine-HCl (pH 2.2)
[17], and 100 μl of 1 mM ATP or 1 mM D-Ala-D-Ala for
30 min. The DNA of ten phages was prepared and
sequenced with a -96 gIII primer (New England Biolabs)
for each elution condition [23].
Bioinformatic analysis of the MurFp1 sequence
The consensus peptide sequence (TMGFTAPRFPHY) iden-
tified by phage display bio-panning was named MurFp1.
The MurFp1 peptide sequence was characterized using dif-
ferent bioinformatic analysis algorithms of the ExPasy
server including the Compute pI/Mw and ProtParam tools
[44] as well as the PSIpred and SSpro secondary structure
prediction tools [45]. The MurFp1 sequence was also ana-
lyzed using the fasts34 program from the FASTA software
package, previously identified as the most efficient tool
for identifying proteins with similarities to small peptide
sequences [18,46].
Synthesis and purification of UDP-MurNAc-Ala-Glu-meso-
A2pm
Synthesis of the UDP-MurNAc-Ala-Glu-meso-A2pm sub-
strate was performed as previously described [47] except
that the reactions starting from UDP-N-acetylglucosamine
were carried out in a single mixture using the combined
activities of P. aeruginosa enzymes MurA, MurB, MurC,
MurD and MurE. The product was purified from the reac-
tion mixture by first removing the Mur enzymes by ultra-
filtration. The ultrafiltrate was then purified by anion
exchange chromatography at room temperature on DEAE-
Sephacel pre-equilibrated in 10 mM ammonium acetate
at pH 7.5, using a 10–800 mM ammonium acetate (pH
7.5) gradient for elution. UDP-MurNAc-Ala-Glu-meso-
A2pm was identified by a pyruvate kinase/lactate dehy-
drogenase coupled assay for D-Ala-D-Ala-dependent ADP
generation by MurF. Fractions thus found to contain
UDP-MurNAc-Ala-Glu-meso-A2pm were freeze-dried
from water three times to remove the ammonium acetate.
Product purity was assessed by FPLC analytical anion
exchange on MonoQ™ using a 0–0.5 M ammonium ace-
tate gradient. Structure of the purified UDP-MurNAc-Ala-
Glu-meso-A2pm was characterized using negative ion
electrospray mass spectrometry, and the synthesized
product was stored frozen in water.
Characterization of MurF activity by spectrophotometric 
assay
The ATPase activity of P. aeruginosa MurF was quantified
by a colorimetric assay that measures the release of
nanomoles of inorganic phosphate using the Lanzetta rea-
gent [48]. The reaction mixture (100 μl), held at room
temperature, contained 40 nM of purified MurF from a
fresh aliquot, 1 mM ATP, 100 μM UDP-MurNAc-Ala-Glu-
meso-A2pm and 5 mM D-Ala-D-Ala in buffer C (100 mM
Tris-HCl pH 8.6, 40 mM KCl, 500 mM NaCl, 1 mg/ml
bovine serum albumin and 10 mM MgCl2) [6]. Reaction
time was 15 min before adding 800 μl of the Lanzetta rea-BMC Biochemistry 2008, 9:33 http://www.biomedcentral.com/1471-2091/9/33
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gent. After an additional 5 min for colour development,
100 μl of 34% (w/v) sodium citrate was added to stop the
reaction [48]. The optical density at 660 nm was immedi-
ately measured with a Cary spectrophotometer (Varian,
Mississauga, Ontario, Canada). The amount of inorganic
phosphate released by MurF was determined by compari-
son to the linear portion of a phosphate standard curve
with a minimum R2 value of 0.99. The phosphate content
of each component in the reaction was subtracted from
the total phosphate measured, negative controls were
done without enzyme or substrate, and assays were done
in triplicate. Different concentrations of each substrate
and NaCl were tested to determine optimal conditions for
the study of the activity of MurFp1.
The maximal specific activity, the catalytic constant (kcat),
the Michaelis-Menten constant (Km) and the enzyme effi-
ciency (kcat/Km) were determined for MurF with respect to
D-Ala-D-Ala. Kinetic parameters were determined by non-
linear regression analysis with a square matrix of enzyme
velocities following the Michaelis-Menten equations
using the Enzyme Kinetics Module version 1 of SigmaPlot
version 8.
Kinetics of MurF inhibition by MurFp1
MurFp1 was synthesized and purified as previously
described [17]. Peptide purity (> 95%) was analyzed by
HPLC and molecular mass (1424.68 daltons) was con-
firmed by MALDI-TOF mass spectroscopy. The peptide
was dissolved in buffer B (200 mM Tris-HCl pH 8.0) at a
final concentration of 100 mM and the pH was adjusted
to 7.0.
Inhibition of MurF enzymatic activity by MurFp1 was
measured by the spectrophotometric assay described
above. The substrates were added after 30 min of pre-incu-
bation of MurF with MurFp1 and the specific activity of
MurF was compared with and without MurFp1. Tests were
also done in which UDP-MurNAc-Ala-Glu-A2pm was
added for pre-incubation with MurF and MurFp1. The
concentration of MurFp1 required to reach 50% inhibi-
tion (IC50) was determined and pre-incubations for 0, 5,
10, 30 and 60 min with 2 mM MurFp1 were tested. The
effect of non-specific peptides was analysed on MurF
enzymatic activity, with and without UDP-MurNAc-Ala-
Glu-A2pm in the pre-incubation step.
To identify potential interactions between MurFp1 and
the MurF substrates, each substrate was added for pre-
incubation with MurF, with or without 2 mM MurFp1.
The MurFp1 inhibitory constant (Ki) was determined for
D-Ala-D-Ala using reaction velocity data obtained with a
30 min pre-incubation of MurF with UDP-MurNAc-Ala-
Glu-A2pm and MurFp1. Inhibitor concentrations tested
were 0, 75, 150, 300 and 600 μM with D-Ala-D-Ala con-
centrations of 50, 100, 250, 500 and 1000 μM, using fixed
optimal concentrations of the remaining substrates.
Kinetic data were fitted to the appropriate model equa-
tions using the Sigmaplot Enzyme Kinetics Module.
Steady-state inhibition kinetic parameters were deter-
mined by nonlinear regression analysis using the least
squares method as a reference to ensure accurate dataset
fitting and to generate error estimates for each individual
observation. The Michaelis-Menten plot of MurF initial
velocity as a function of substrate concentration was used
to determine the apparent kinetic parameters Vmax and Km
with respect to D-Ala-D-Ala using equation 1 [41,42]:
v = Vmax * [S]/(Km + [S]) (1)
The type of inhibition was identified using the
Lineweaver-Burk plot of reciprocal MurF initial velocity to
reciprocal D-Ala-D-Ala concentration for the various
MurFp1 concentrations. Competitive Ki value was deter-
mined using the Dixon graphic re-plotting of reciprocal
initial velocity versus MurFp1 concentration for each sub-
strate concentration, which provides the inhibition com-
ponents regardless of the inhibition type according to
equation 2:
v = Vmax*((1+β*I/(α*Ki))/(1+I/(α*Ki)))/(1+Km/S)*(1+I/
Ki)/(1+I/(α*Ki))) (2)
where Vmax is the maximum initial velocity for the unin-
hibited MurF reaction, I is MurFp1, Km is the Michaelis
constant for the uninhibited reaction, α is the Km factor
change when MurFp1 is bound to the MurF-D-Ala-D-Ala
complex (ES) and β is the Kp (the rate constant when ES
breaks down to enzyme and product) factor change when
MurFp1 is bound to ES [41,42].
The non-competitive Ki was calculated using equation 3:
v = Vmax/((1+Km/S)*(1+I/Ki)/(1+I*β/Ki)) (3)
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